Habit Modification of the Active Pharmaceutical Ingredient Lovastatin Through a Predictive Solvent Selection Approach

Thomas D. Turner 1,*, Lauren E. Hatcher 2, Chick C. Wilson 2, Kevin J. Roberts 1
1 Centre for the Digital Design of Drug Products, School of Chemical and Process Engineering, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK
2 Future Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub, Department of Chemistry, University of Bath, Bath BA2 7AY, UK

Keywords:
- molecular modeling
- synthonic engineering
- surface chemistry
- morphology prediction
- lattice energy
- lovastatin

Abstract

An analysis of the important intermolecular interactions of the active pharmaceutical ingredient lovastatin which contribute to the surface chemistry and attachment energy morphology is presented. The analysis is supported by a recent redetermination of the single-crystal structure (orthorhombic space group P212121) and targets the understanding and potential control of the morphology of lovastatin, which tends to crystallize in a needle-like morphology, where the aspect ratio varies depending on the nature of the solvent. The lattice energy was calculated to be 38.79 kcal mol⁻¹ with a small contribution of 2.73 kcal mol⁻¹ from electrostatic interactions. The lattice structure is significantly stabilized by the hexahydronaphthalene ring of the molecule, which contributes 43.39% of the lattice energy. Synthon analysis shows that the dominant intermolecular interaction within the lattice structure of lovastatin is found to be along the c axis, associated with a dispersive stacking interaction due to the close packing of 2 hexahydronaphthalene rings resulting in a total interaction energy of 6.46 kcal mol⁻¹.

The attachment energy morphology correlates well with the observed crystal morphology which exhibits a needle-like habit dominated by (011), (020), (002), and (101) crystal forms. The needle capping faces are found to contain the short stacks of hexahydronaphthalene rings where the strong intermolecular synthon is found to contribute positively to the attachment energy and hence growth at this surface. This dominant intermolecular synthon is concluded to be the major cause of enhanced growth along the crystallographic c axis leading to the formation of a needle-like morphology. A habit modification strategy is discussed which uses recrystallization from apolar solvents to reduce the effective growth rate at the needle-capping surfaces. This is supported through experimental data which shows that crystals obtained from crystallization in hexane and methyl-cyclohexane have significantly reduced aspect ratios in comparison to those grown from the more polar methanol and ethyl acetate solutions. Crystals obtained from nitromethane solutions were also found to have a very large reduction in aspect ratio to a prismatic morphology reflecting this solvent's propensity to interact with hydrophobic surfaces, critically with no polymorph change.

Introduction

Mevinolinic acid or lovastatin belongs to the statin class of drug compounds, one of the most widely prescribed drug classes worldwide for the treatment of hypercholesterolemia. Lovastatin targets and inhibits the enzyme hydroxymethylglutaryl coenzyme A reductase, which plays a key role in initiating the synthesis of cholesterol; hence, lovastatin hinders the biosynthesis pathway of cholesterol. Lovastatin is generally isolated through a chemical synthesis or biosynthesis fermentation route, where the product is then isolated and purified through a recrystallization strategy, generally from alcohol or acetone/water mixes.

Lovastatin has been the target of many physicochemical screening studies within the literature due to its importance as an industrial active pharmaceutical ingredient (API). The solid-state physicochemical properties of lovastatin have been studied using thermal analysis methods; the melting point was found to be 445 K and where the crystalline material undergoes amorphization when recrystallized with the preservative butylhydroxyanisole. The sol-ubility of lovastatin was measured in a number of solvent systems, namely in a series of homologous acetates, alcohols, and also in...
of lovastatin in relation to its observed needle-like morphology. Additionally, it aims at quantifying the extrinsic (surface-terminat ed) synthon contribution to the attachment of molecules at the growing crystal surfaces. This is part of an overall strategy to effect the habit modification of this material to mitigate the impact of the observed needle-like morphology of lovastatin by providing a fundamental molecular understanding of both the crystallographic structure and the nature of the interactions of the solute with its surrounding solution environment.

Materials and Methods

Chemicals

Lovastatin was used as supplied by the EPSRC Future Continuous Manufacturing and Advanced Crystallisation Research Hub and originally purchased through Molekula. Ethyl acetate HPLC >99.95%, methanol HPLC 99.61%, and hexane HPLC 99.9% purity were used as supplied by Fisher. Toluene reagent grade >99.7% and methyl cyclohexane anhydrous >99% were used as supplied by Sigma-Aldrich.

Experimental Methodology

Single-Crystal X-Ray Diffraction

Single crystals of lovastatin (colorless needles) were obtained by slow evaporation from saturated ethyl acetate, methanol, methyl cyclohexane, toluene, hexane, and nitromethane solutions at 25°C. Single-crystal X-ray diffraction data were recorded at the University of Bath, on a dual-source Rigaku Oxford Diffraction Gemini A Ultra diffractometer, equipped with an Atlas CCD detector and an Oxford Cryosystems Cryojet-XL liquid nitrogen flow device for temperature control. Data collection, indexing, and integration procedures were performed using the Rigaku Oxford Diffraction software CrysAlis Pro. Using Olex2, the structure was solved by dual-space methods using ShelXT and refined by least squares methods using ShelXL. Hydrogen atoms were positioned geometrically and refined using a riding model. The hydrogen atom isotropic displacement parameters were fixed to $U_{iso}(H) = 1.5$ (for CH$_3$) or $U_{iso}$ (H) = 1.2 (for CH$_2$ and CH) the $U_{eq}$ of the parent atom. The structure is included in the Cambridge Structural Data-base as a CSD Communication with CSD refcode CEKBEZ01.

Powder X-Ray Diffraction

Powder X-ray diffraction was used for polymorph characterization of the prepared lovastatin crystals from slow solvent evaporation. The powder samples were ground to a powder using a mortar and pestle then mounted on a single-cut silicon crystal powder holder and scanned using a Bruker D8 advanced X-ray diffractometer using Cu Ka radiation and a germanium primary mono-chromator in Bragg-Brentano reflection geometry. The step size was 0.033 2θ with a step time of 0.7 s/step over a 2θ range of 2-39.8 2θ. The detector used was a Vantec-1 position-sensitive detector.

Modeling Methodology

Visualization of the crystal structure was carried out using the Cambridge Crystallographic Data Centre’s Mercury software. The conformational analysis of lovastatin (CEKBEZ01) was performed using the Forcite module in Accelrys Materials Studio where the geometry of a single Lovastatin molecule of the major disorder component was optimized with respect to the potential energy surface to minimize the total energy of the structure. The PCFF forcefield was used and the atomic charges were calculated using Gasteiger’s SMART algorithm. The geometry of this gas phase optimized...
molecule of lovastatin was then compared to the conformation of the molecule in the crystal structure.

The lattice, slice, and attachment energies were calculated using an atom-atom summation method using Habit98 \(^{1,2,11}\) using the Momany \(^{15}\) potential where the atomic charges were calculated within Mopac \(^{46}\). Habit98 builds a series of unit cells which expand outward from a central unit cell; the intermolecular interaction between a central molecule and all others within an expanding sphere, the radius of which was set as 1-30 Å to ensure lattice energy convergence, is calculated. The resulting lattice energy was partitioned into the slice and attachment energy based on Equation 1.

\[
E_{cr} = \frac{1}{4} E_{sl} + \frac{3}{4} E_{att}
\]

(1)

where \(E_{cr}\) is the lattice energy, \(E_{sl}\) is the slice energy, and \(E_{att}\) is the attachment energy. The important morphological faces were selected based upon the Bravais, Friedel, Donnay, and Harker (BFDH) rule \(^{46-48}\) which states the surfaces with lowest surface energy will be those with the greatest interplanar d-spacing and were chosen using the Morphology tool with Materials Studio. The predicted morphology was calculated using the top 10 crystal planes sorted by the highest d-spacing where the attachment energy of those faces was calculated and the attachment energy was approximated to a surface-specific growth rate. The morphology was then reconstructed using a Wulff plot using SHAPE \(^{50,51}\). The surface anisotropy factors, \(\varepsilon_{hkl}\), which describe the termination of the synthons at a specific habit face, were calculated using Equation 2 and expressed as a percentage. The plane rugosity of the crystal faces was calculated based on the average root mean square displacement of the atomic centers of the molecules in the unit cell along the growth normal within the d-spacing of the crystallographic planes. The plane rugosity provides a simple measure of the variation in height for a given crystallographic plane and hence provides a description of the smoothness for a given crystal plane at an atomic level. The intermolecular synthons were analyzed and ranked by their total intermolecular energy contribution to the overall lattice energy of lovastatin following a methodology previously reported by Rosbottom et al. \(^{17}\)

**Results**

**Single-crystal Structure Determination**

The single-crystal structure of lovastatin (CSD refcode CEKBEZ) was first published by Sato et al. \(^{52}\) in 1984 and was determined from room temperature X-ray diffraction data. The data presented in this article are a modern redetermination of the structure at low temperature (150 K), confirming that the overall structure of lovastatin remains largely unchanged on cooling, and the crystal structure refinement data of lovastatin are provided in S2 of the Supplementary Information. No structural phase transition is observed on cooling, with the same P2\(_1\)2\(_1\)2\(_1\) space group retained at 150 K and slightly reduced unit cell parameters, as is in keeping with thermal contraction on cooling (overall decrease in unit cell volume \(\frac{1}{4}\) ca. 2%). An overlay of the 2 structures in the CSD software Mercury \(^{53}\) confirms that the molecular conformation is largely unchanged on cooling, with a root mean square deviation of 0.0214 calculated between the 2 structures (see Supplementary Information, S2 Fig. 2). The key difference between the new structure and that published by Sato et al. is that disorder in the S-butanote ester group was resolved at low temperature. The S-butanote group is found to be disordered over 2 positions and was freely refined using standard PART \(^{32}\) instructions to determine a ratio of 57% of the major component and 43% of the minor component (see Supplementary Information, S2 Fig. 3). The conformation of the major component overlays well with the reported room temperature arrangement for this group (see Supplementary Information, S2 Fig. 2). Although no disorder was reported by Sato et al., analysis of their original structure data does show that the anisotropic displacement parameters for the S-butanote chain are significantly larger than for the rest of the structure (e.g., the reported anisotropic displacement parameter for the carbon atom of the terminal CH\(_3\) group is ca. 2\% larger than that of other CH\(_3\) groups in the structure). \(^{52}\) These observations indicate that the presence of disorder cannot be entirely ruled out in the room temperature structure and are thus consistent with our own observations at low temperature. It should also be noted that the data quality is also remarkably improved in the 150 K redetermination, with a residual factor R1 \(1\% 3.17\%\) in comparison to R1 \(4\% 8.2\%\) for the original dataset. A reduction in data quality at room temperature is common and hence may reasonably have prevented reliable assessment of any potential disorder in the structure.

The single-crystal structure of lovastatin (CSD refcode CEKBEZ) was first published by Sato et al. \(^{52}\) in 1984 and was determined from room temperature X-ray diffraction data. The data presented in this article are a modern redetermination of the structure at low temperature (150 K), confirming that the overall structure of lovastatin remains largely unchanged on cooling, and the crystal structure refinement data of lovastatin are provided in S2 of the Supplementary Information. No structural phase transition is observed on cooling, with the same P2\(_1\)2\(_1\)2\(_1\) space group retained at 150 K and slightly reduced unit cell parameters, as is in keeping with thermal contraction on cooling (overall decrease in unit cell volume \(\frac{1}{4}\) ca. 2%). An overlay of the 2 structures in the CSD software Mercury \(^{53}\) confirms that the molecular conformation is largely unchanged on cooling, with a root mean square deviation of 0.0214 calculated between the 2 structures (see Supplementary Information, S2 Fig. 2). The key difference between the new structure and that published by Sato et al. is that disorder in the S-butanote ester group was resolved at low temperature. The S-butanote group is found to be disordered over 2 positions and was freely refined using standard PART \(^{32}\) instructions to determine a ratio of 57% of the major component and 43% of the minor component (see Supplementary Information, S2 Fig. 3). The conformation of the major component overlays well with the reported room temperature arrangement for this group (see Supplementary Information, S2 Fig. 2). Although no disorder was reported by Sato et al., analysis of their original structure data does show that the anisotropic displacement parameters for the S-butanote chain are significantly larger than for the rest of the structure (e.g., the reported anisotropic displacement parameter for the carbon atom of the terminal CH\(_3\) group is ca. 2\% larger than that of other CH\(_3\) groups in the structure). \(^{52}\) These observations indicate that the presence of disorder cannot be entirely ruled out in the room temperature structure and are thus consistent with our own observations at low temperature. It should also be noted that the data quality is also remarkably improved in the 150 K redetermination, with a residual factor R1 \(1\% 3.17\%\) in comparison to R1 \(4\% 8.2\%\) for the original dataset. A reduction in data quality at room temperature is common and hence may reasonably have prevented reliable assessment of any potential disorder in the structure.
Lattice Energy and Intermolecular Synthon Analysis

The lattice energy of lovastatin converged at 38.79 kcal mol\(^{-1}\) where the electrostatic contribution converges at 2.73 kcal mol\(^{-1}\) at a maximum convergence distance of 30 Å. The lattice energy and electrostatic contribution energy as a function of limiting radius are provided in Figure 3a, and this shows that the lattice energy converges in 2 shells, the first at 6-9 Å and the second at 13 Å as shown in Figure 3b. The very low contribution to the lattice energy provided by electrostatic interactions is unsurprising considering the largely dispersive nature of the lovastatin molecule.

The lattice energy of lovastatin was further collapsed onto the asymmetric molecular unit to provide a quantitative analysis of the relative functional group contribution to stabilizing the crystal lattice. Figure 4a provides this quantitative breakdown onto the lovastatin molecule where the hexahydronaphthalene group (\(\text{a}\)) contributes 43.39% of the lattice energy, indicating the importance of dispersive interactions within the lovastatin lattice structure. The tetrahydropyran functionality (\(\text{b}\)) contributes 29.42% and the S-butanoate ester group (\(\text{g}\)) contributes 27.24%; interestingly, the \(\text{b}\) group contains the acidic proton short contact between the carbonyl group of the tetrahydropyran ring and the protons of an adjacent tetrahydropyran ring. Whereas the \(\text{g}\) group contains the long-range H-bond (\(\sim\)2.0 Å) from the ester functionality, this highlights the subtle differences between the H-bonding component and the short contact component to the lattice energy where the acidic proton short contact seems to play a greater role in contributing to the stabilization of the lattice structure.

Figure 4b summarizes the top 7 intermolecular synthons, ranked by intermolecular interaction energy, which contribute to the lattice energy of lovastatin, additionally Table 1 summarizes the breakdown of these synthonic interactions into attractive, repulsive, coulombic, and total energy from the field calculation. Synthon A provides the largest contribution to the lattice energy of lovastatin, 6.46 kcal/mol and 33.31% of the total lattice energy, \(\sim\) 3.5 kcal/mol greater than synthon B which highlights the importance of this close-packed interaction which is \(~\)98% dominated by dispersive interactions between the hexahydronaphthalene groups as summarized in Table 1. Synthons B and E contain a larger coulombic component, \(~\)20% and 26% contribution to the overall interaction, respectively. This is due to the hydrogen bond between the alcohol proton and carbonyl oxygen in synthon B and the acidic proton short contact in synthon E as shown in Figure 4b. Synthons F and G provide a relatively small contribution to the overall crystal lattice energy with weak dispersive-type interactions of 1.05 and 0.92 kcal/mol, respectively. These 7 synthons provide 93.06% of the total lattice energy of lovastatin and hence analysis of further intermolecular synthons was not carried out due to their low contribution to the overall lattice energy.

The strongest intermolecular synthon, Synthon A, comprises of a close-stacked interaction of the hexahydronaphthalene rings. Figure 4b provides a schematic of Synthon A with the breakdown of the interaction energy onto the functional groups of lovastatin. This shows that the hexahydronaphthalene rings provide 54.66% of the interaction energy and the \(\text{b}\) and \(\text{g}\) functional groups provide 23.40% and 21.52%, respectively. Further to this, it was found that the components of this intermolecular interaction energy are dispersive in nature as highlighted by the breakdown of the energy into dispersive and coulombic components as highlighted in Table 1.

Attachment Energy Morphology and Surface Chemistry

The attachment energy morphology of lovastatin is provided in Figure 5 where the simulation yields a needle-like morphology.

---

Figure 1. The crystal structure of lovastatin viewed down the a and c axes.

Figure 2. Conformational overlay of the gas phase optimized lovastatin molecule and the molecule in the asymmetric unit of lovastatin.
Figure 3. Convergence of the calculated lattice total energy and the % contribution to the lattice energy.

Figure 4. (a) The percentage contribution to the lattice energy provided by the 3 functional groups of the lovastatin asymmetric unit and the top 7 intermolecular synthons which contribute to the lattice energy of lovastatin.
Table 1
The Top 7 Intermolecular Synthons Which Contribute to the Lattice Energy of Lovastatin, Ranked in Order of Total Interaction Energy; Also Provided Is the Contribution of Each Synthon to the Total Lattice Energy and Also the Contributions in Multiplicity of Synthons to the Surfaces Present in the Attachment Energy Morphology

<table>
<thead>
<tr>
<th>Synthon</th>
<th>Distance/Å</th>
<th>Dispersive</th>
<th>Coulombic</th>
<th>Total</th>
<th>% Contribution of Lattice Energy</th>
<th>Contribution to {0 1 1} Attachment Energy</th>
<th>Contribution to {0 2 0} Attachment Energy</th>
<th>Contribution to {1 0 1} Attachment Energy</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>5.89</td>
<td>6.31</td>
<td>0.16</td>
<td>6.46</td>
<td>33.31</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>B</td>
<td>11.11</td>
<td>2.47</td>
<td>0.50</td>
<td>2.98</td>
<td>15.36</td>
<td>2</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>C</td>
<td>10.35</td>
<td>2.58</td>
<td>0.02</td>
<td>2.56</td>
<td>13.20</td>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>D</td>
<td>10.03</td>
<td>2.04</td>
<td>0.08</td>
<td>2.12</td>
<td>10.93</td>
<td>2</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>E</td>
<td>11.39</td>
<td>1.45</td>
<td>0.51</td>
<td>1.96</td>
<td>10.11</td>
<td>2</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>F</td>
<td>11.11</td>
<td>0.92</td>
<td>0.13</td>
<td>1.05</td>
<td>5.41</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>G</td>
<td>11.91</td>
<td>0.90</td>
<td>0.01</td>
<td>0.92</td>
<td>4.74</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

Total % = 93.06%

*Distance is calculated from the center of gravity of the 2 molecules contributing to the intermolecular interaction.*

dominated by {0 1 1}, {0 2 0}, {1 0 1}, and {0 0 2} surfaces, where the {1 0 1} surfaces are the needle capping faces. The calculated attachment energy morphology is in reasonably good agreement with micrographs of lovastatin crystals grown from ethyl acetate and toluene solutions, shown in Figure 6 which present as needle-like crystallites albeit of a higher aspect ratio in comparison to the model morphology, a more detailed figure of the calculated attachment energy morphology is provided in S5 in the Supplementary Information.

Table 2 summarizes the slice, attachment energy, and % surface saturation of the top 10 BFDH face list of lovastatin, where the highlighted faces are those which are present in the calculated attachment energy morphology. Interestingly, the % surface saturation of the morphologically important surfaces correlates well to the morphology, whereby the needle capping surfaces, {1 0 1}, have by far the lowest surface saturation, 30.21%, meaning growth in this direction would be favored due to unsatisfied surface-active inter-molecular interactions. Conversely, the slow-growing {0 1 1} sur-face has the highest surface saturation, 66.69%, meaning growth is likely to be slower in this direction.

The overall contribution of the top 5 intermolecular synthons, presented in Figure 4, to the attachment energy of the {0 1 1}, {0 2 0},

![Figure 5](image-url) Attachment energy morphology of lovastatin together with the surface chemistry of the habit planes.
and $\{011\}$ surfaces was calculated to assess the relative importance to the growth of these faces. This analysis is summarized in Table 1 where the multiplicity of each synthon is presented. This analysis shows that, interestingly, the needle capping $\{101\}$ surface is the only morphological surface to contain Synthon A as an extrinsic growth synthon. This correlates well with the observation that the morphology is extended down the $a$ axis through this surface. Conversely, the larger, slower-growing $\{011\}$ surface has no contribution from Synthon A to its attachment energy and only has the lower-energy synthons B, C, D, and E with a multiplicity of 2, as extrinsic synthons.

A visualization of the surface chemistry for the $\{011\}$, $\{020\}$, and $\{101\}$ surfaces of lovastatin is provided in Figure 5. This indicates the close-packed nature of the $\{101\}$ needle capping surface and shows the relative availability of the hexahydronaphthalene rings at the surface which can provide stacking interactions to form the energetically favorable Synthon A, which was highlighted in the previous analysis, and contributes to the attachment energy at this surface. Additionally, the calculated plane rugosity (Table 2) of the $\{101\}$ surface was found to be 2.61 Å which is low relative to the $\{011\}$ and $\{020\}$ surfaces. This could provide a more favorable growth environment, whereby desolvation of the surface followed by solute integration is to some extent less rate limited by the desolvation step due to solvent trapping at the surface for example. Conversely, the $\{011\}$ and $\{020\}$ surfaces have significantly higher calculated plane rugosity than the needle capping surface, which could impact desolvation, where the channels trap solvent and hence decrease the rate of desolvation and effectively decrease the growth rate at these surfaces relative to the needle capping surface.
Synthonic and Surface Chemistry Analysis in Relation to the Needle Morphology of Lovastatin

This analysis has indicated the importance of Synthon A, not only in contributing to the stabilization of the lattice structure of lovastatin but also in contributing to the attachment energy as an extrinsic synthon on the needle capping \{1 0 1\} surface. The combination of a highly favorable dispersive stacking interaction between the 2 hexahydronaphthalene groups, the low calculated \{1 0 1\} plane rugosity, and the availability of the hexahydronaphthalene groups at the capping surface are likely the cause of the formation of a needle-like morphology due to faster crystal growth along the crystallographic a axis of lovastatin.

The identification of Synthon A, not only as an important possible growth synthon but also as an extrinsic synthon at the needle capping face, leads to the postulation of a crystallization strategy to hinder or at least reduce the aspect ratio of the crystals through selective binding of the hexahydronaphthalene rings to hinder formation of Synthon A. Micrographs of lovastatin crystals obtained from slow solvent evaporation in some nonpolar solvents are provided in Figure 6. This highlights that in methyl cyclohexane, toluene, hexane, and nitromethane solutions, the crystallites recovered had a significantly lower aspect ratio when compared to those grown in polar protic or polar aprotic solvents such as methanol and ethyl acetate. This is likely due to selectively binding of the apolar component of the lovastatin molecule which would effectively decrease the desolvation rate of the molecule at the hexahydronaphthalene group in the solution state, hindering the formation of Synthon A and also decrease the desolvation rate of the \{1 0 1\} capping face relative to the side and top faces. This reduction in relative growth rate would likely decrease the aspect ratio to a more equant morphology.

Nitromethane provides an interesting result as this solvent considerably reduces the aspect ratio of the lovastatin crystals to a prismatic-like morphology. The crystals obtained were analyzed for polymorph changes, where powder X-ray diffraction showed the crystals to be of the same crystal structure and hence no polymorph change or solvate formation had taken place, these data are provided in S6 of the Supplementary Information. The cause of this dramatic reduction in needle-like morphology is likely to be the prevention of Synthon A formation and the reduction in the growth rate on the needle capping face. This dramatic habit modification has also been shown for the case of p-amino benzoic acid, where the needle-like alpha form can be reduced to a significantly more prismatic crystal habit through recrystallization from nitromethane solutions. This was found to be caused by interaction of nitro-methane with the benzene rings of p-amino benzoic acid and hence disrupting strong p·p stacking interactions which cause the needle-like morphology in the material. This is also likely the case for lovastatin, where the nitromethane could preferentially bind to the hexahydronaphthalene ring system, probably through the unsaturated carbon atoms, and hence prevent Synthon A formation.

The effect of “blocking” Synthon A using solvation could also be similarly achieved through additive addition using the same principle. Additives such as polyaromatic or polycyclic hydrocarbons, for example, naphthalene, could have the same effect by blocking Synthon A and also through disruption of the molecular recognition at the \{1 0 1\} capping surface, reducing the effective growth rate.

Conclusions

A molecular modeling analysis of the intrinsic and extrinsic synthons of the API lovastatin in relation to its bulk and surface properties has been presented to rationalize the materials’ observed needle-like morphology. The synthetic analysis revealed a strong intermolecular interaction in the bulk structure which consisted of a close-packed stacking interaction of 2 hexahydronaphthalene rings. This intermolecular interaction was found to be ~3.5 kcal mol\(^{-1}\) more energetically favorable than the second strongest synthonic interaction in the bulk structure. Additionally, the hexahydronaphthalene ring of lovastatin was found to contribute 43.39% of the calculated lattice energy of the material, where 99.83% of this was found to be of a dispersive nature.

The calculated attachment energy morphological model correlated reasonably well with the experimental morphology observed for crystals grown from ethyl acetate solutions and was dominated by \{0 1 1\}, \{0 2 0\}, \{1 0 1\}, and \{0 0 2\} surfaces. Analysis of the surface chemistry of the habit faces revealed that the \{1 0 1\} needle capping face was highly undersaturated with respect to its extrinsic synthons, where the surface saturation was calculated as 30.21%, compared to 66.69% and 44.93% for the slower growing \{0 1 1\} and the \{0 2 0\} surfaces, respectively. The \{1 0 1\} needle capping face also was found to have a lower plane rugosity, 2.61 Å, compared to 5.88 Å and 7.22 Å for the \{0 2 0\} and \{0 1 1\} faces, respectively. The analysis of the surface chemistry revealed that critically, Synthon A contributes positively to the attachment energy of the \{1 0 1\} capping surface and does not contribute to the attachment energy of either the \{0 2 0\} or \{0 1 1\} faces. Hence, it was concluded that Synthon A is the major cause for the formation of a needle-like morphology in lovastatin down the crystallographic a axis and a recrystallization strategy using apotic or apolar solvents or additives could be used as habit modifiers for this material to reduce the aspect ratio of the crystals.

Acknowledgments

This work was funded by the Advanced Manufacturing Supply Chain Initiative “Advanced Digital Design of Pharmaceutical
52. Hammond RB, Pencheva K, Roberts KJ. A structural kinetics approach to model face-specific solution/crystal surface energy associated with the crystallization of macrolides.